{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:18:58Z","timestamp":1780633138975,"version":"3.54.1"},"reference-count":104,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,7,16]],"date-time":"2004-07-16T00:00:00Z","timestamp":1089936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Nausea and vomiting are preventable side effects of cancer chemotherapy for children. Antiemetics are essential, especially as treatment becomes more intensive. Many drugs are available, but adequate evidence\u2010based recommendations are lacking. We aimed (1) to consider an evidence\u2010based approach for pharmacological prophylaxis of chemotherapy\u2010induced nausea and vomiting (CINV) in children, and (2) to compare this approach with antiemetic prescribing in two paediatric oncology centres.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Relevant publications (Medline, Embase, CancerLit:1966\u20132002) were critically evaluated using pre\u2010defined criteria. Evidence\u2010based statements summarising their findings were formulated, and evidence basis proposed. Current prescribing practice was then compared with this evidence basis in Welsh children under 16 receiving chemotherapy at Llandough Hospital, Cardiff or Alder Hey Children's Hospital, Liverpool between 1 January 2001 and 31 December 2001.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 213 studies retrieved, 82 provided evidence. Our evidence basis recommends combination 5HT<jats:sub>3<\/jats:sub>\u2010antagonist\/corticosteroid for highly emetogenic chemotherapy, 5HT<jats:sub>3<\/jats:sub>\u2010antagonist alone for moderate emetogenicity, and no antiemetic for other chemotherapy. Forty\u2010four children in Cardiff (0.6\u201316.9 yrs) and 14 in Liverpool (0.8\u201316.2 yrs) were included in the audit. Differences in prescribing practice between the centres were not significant. In 109\/159 (69%) of chemotherapy courses (35, 87 and 100% of high, moderate and low emetogenicity, respectively), antiemetics were selected in accordance with evidence basis. Seventy percent of prescribed doses were as evidence basis recommended.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We present an evidence basis for prescribing prophylactic antiemetics to children undergoing chemotherapy. Prescribing practices in these two centres treating Welsh children were similar. Both differed from the evidence basis we propose. Deviations were greatest for regimens of high emetogenicity, where effective emetic control is most crucial. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20138","type":"journal-article","created":{"date-parts":[[2004,7,16]],"date-time":"2004-07-16T20:04:28Z","timestamp":1090008268000},"page":"651-658","source":"Crossref","is-referenced-by-count":21,"title":["Prophylaxis of acute chemotherapy\u2010induced nausea and vomiting in children with cancer: What is the evidence?"],"prefix":"10.1002","volume":"43","author":[{"given":"Emmanuel S.","family":"Antonarakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma F.","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy M.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry L.","family":"Pizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.W.","family":"Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,16]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"14","article-title":"Consortium for the Prevention and Management of the Serious Side Effects of Cancer Chemotherapy","volume":"6","author":"Anonymous. Preventing and managing the serious side effects of cancer chemotherapy","year":"1997","journal-title":"J Oncol Manag"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1188\/02.CJON.94-102"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010548"},{"key":"e_1_2_6_5_2","first-page":"547","article-title":"Anticipatory nausea and vomiting in pediatric cancer patients","volume":"75","author":"Dolgin MJ","year":"1985","journal-title":"Pediatrics"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050156"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200103060-00007"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00042310-200218030-00001"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.103"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.71.5.475"},{"key":"e_1_2_6_11_2","first-page":"57","article-title":"NCCN antiemesis practice guidelines","volume":"11","author":"National Comprehensive Cancer Network","year":"1997","journal-title":"Oncology"},{"key":"e_1_2_6_12_2","first-page":"197","article-title":"MASCC international (Perugia) consensus on antiemetic therapy","volume":"6","author":"Multinational Association of Supportive Care in Cancer","year":"1998","journal-title":"Support Care Cancer"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2971"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ajhp\/56.8.729","article-title":"ASHP therapeutic evidence basis on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery","volume":"56","author":"American Society of Health\u2010System Pharmacists","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017413507554"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00365578"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.116"},{"key":"e_1_2_6_18_2","volume-title":"Project for the enhancement of the Welsh protocols for investment in health gain: Project methodology 4","author":"Weightman AL","year":"2001"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199505000-00008"},{"key":"e_1_2_6_20_2","first-page":"2369","article-title":"Antiemetic efficacy of granisetron in pediatric cancer treatment. Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis","volume":"20","author":"Hirota T","year":"1993","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00822-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907293410507"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2003.08.028","article-title":"The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin\u2010based chemotherapy: A combined analysis of two randomised, placebo\u2010controlled phase III clinical trials","volume":"40","author":"de Wit R","year":"2004","journal-title":"Eur J Cancer"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00048.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00602.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.3.1.45"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.8.1136"},{"key":"e_1_2_6_29_2","first-page":"104","article-title":"Dose\u2010related extrapyramidal effect of metoclopramide in children receiving chemotherapy","volume":"3","author":"Graham\u2010Pole J","year":"1984","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808602000205"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80613-7"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1992.tb01279.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80866-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.1984.2.8.930","article-title":"Paradoxical effects of prophylactic phenothiazine antiemetics in children receiving chemotherapy","volume":"2","author":"Zeltzer L","year":"1984","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.7.1110"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6199.1188"},{"key":"e_1_2_6_37_2","first-page":"321","article-title":"Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy","volume":"33","author":"Basade M","year":"1996","journal-title":"Indian Pediatr"},{"key":"e_1_2_6_38_2","first-page":"422","article-title":"Assessment of the efficacy of drugs used in prevention of vomiting during anticancer therapy in children","volume":"45","author":"Gadomski A","year":"1990","journal-title":"Pol Tyg Lek"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)81066-6"},{"key":"e_1_2_6_40_2","first-page":"207","article-title":"Control of vomiting induced by antineoplastic chemotherapy in childhood","volume":"34","author":"Madero\u2010Lopez L","year":"1991","journal-title":"An Esp Pediatr"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(89)80354-3"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)00194-B"},{"key":"e_1_2_6_43_2","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy\u2010induced emesis in children: A double\u2010blind, crossover trial","volume":"79","author":"Chan HS","year":"1987","journal-title":"Pediatrics"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.61.5.502"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1979.tb127271.x"},{"key":"e_1_2_6_46_2","unstructured":"PatelN HuntJ McElwainT.A comparison of the antiemetic efficacy and safety of nabilone and prochlorperazine in paediatric patients with cytotoxic\u2010induced nausea and vomiting. Proceedings of the Second European Conference on Clinical Oncology; Amsterdam1983."},{"key":"e_1_2_6_47_2","first-page":"419","article-title":"The efficacy and safety of ondansetron: A Benelux open non\u2010comparative multi\u2010centre study in children receiving emetogenic chemotherapy","volume":"19","author":"Brock P","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"e_1_2_6_48_2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.1990.8.9.1531","article-title":"Prevention of cyclophosphamide\/cytarabine\u2010induced emesis with ondansetron in children with leukemia","volume":"8","author":"Carden PA","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019509029530"},{"key":"e_1_2_6_50_2","first-page":"1363","article-title":"Use of ondansetron, a 5\u2010HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology","volume":"134","author":"Csaki C","year":"1993","journal-title":"Orvosi Hetilap"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199705000-00114"},{"key":"e_1_2_6_52_2","first-page":"35","article-title":"Evaluation of ondansetron (Zofran) in prevention of vomiting in children treated with cytostatics","volume":"70","author":"Dluzniewska A","year":"1995","journal-title":"Pediatria Polska"},{"key":"e_1_2_6_53_2","first-page":"350","article-title":"Effectiveness of strategies for preventing acute antineoplastic\u2010induced nausea and vomiting in children with acute lymphoblastic leukemia","volume":"52","author":"Dupuis LL","year":"1999","journal-title":"Can J Hosp Pharm"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80686-7"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900103"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050147"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1159\/000227057"},{"key":"e_1_2_6_58_2","first-page":"115","article-title":"Ondansetron as an effective drug in prophylaxis of chemotherapy\u2010induced emesis in children","volume":"24","author":"Kolecki P","year":"1993","journal-title":"Acta Haematol Pol"},{"key":"e_1_2_6_59_2","first-page":"925","article-title":"Estimation of effectiveness of antiemetic treatment with Zofran (ondansetron) given in one dose to children with neoplasms","volume":"70","author":"Kurylak A","year":"1995","journal-title":"Pediatr Pol"},{"key":"e_1_2_6_60_2","first-page":"161","article-title":"Ondansetron, an antagonist of 5\u2010HT3 receptors, in the treatment of antineoplastic drug\u2010induced nausea and vomiting in children","volume":"24","author":"Matera MG","year":"1993","journal-title":"J Med"},{"key":"e_1_2_6_61_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/106002809402800116","article-title":"Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients","volume":"28","author":"McQueen KD","year":"1994","journal-title":"Ann Pharmacother"},{"key":"e_1_2_6_62_2","first-page":"468","article-title":"Intraveous plus oral ondansetron for prevention of emesis in children receiving chemotherapy","volume":"13","author":"Panzarella C","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200112000-00005"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.8.822"},{"key":"e_1_2_6_65_2","first-page":"126","article-title":"Ondansetron in prevention and treatment of vomiting in children with blood malignancies","volume":"43","author":"Rola E","year":"1993","journal-title":"Nowotwory"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200003000-00009"},{"key":"e_1_2_6_67_2","first-page":"369","article-title":"Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children","volume":"105","author":"Sullivan MJ","year":"1992","journal-title":"NZ Med J"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.73.3.243"},{"key":"e_1_2_6_69_2","unstructured":"JimenezM LeonP GimenoJ.Comparison of chlorpromazine plus dexamethasone vs ondansetron vs tropisetron in the treatment of emesis induced by highly and moderately emetogenic chemotherapy in pediatric patients with malignancies. International Society of Pediatric Oncology XXIX Meeting; Istanbul1997."},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050940"},{"key":"e_1_2_6_71_2","first-page":"603","article-title":"Efficacy and safety of oral ondansetron in the control of acute chemotherapy induced nausea and vomiting (ACINV) in chemotherapy\u2010na\u00efve pediatric patients","volume":"18","author":"Pai VB","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00157-8"},{"key":"e_1_2_6_73_2","first-page":"424","article-title":"Evaluation of the anti\u2010emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors","volume":"45","author":"Safonova SA","year":"1999","journal-title":"Voprosy Onkologii"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909909032871"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010050120791"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950250107"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199408000-00008"},{"key":"e_1_2_6_78_2","first-page":"1295","article-title":"Clinical evaluation of granisetron (BRL43694) in nausea and vomiting induced by anticancer drugs\u2010pediatrics","volume":"26","author":"Sawada T","year":"1999","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70568-6"},{"key":"e_1_2_6_80_2","first-page":"2201","article-title":"Antiemetic efficacy of granisetron in the treatment of pediatric cancer. Clinical evaluation of granisetron at a dose of 40 micrograms\/kg","volume":"20","author":"Hirota T","year":"1993","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199408000-00009"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00071-4"},{"key":"e_1_2_6_83_2","first-page":"437","article-title":"A double\u2010blind dose\u2010ranging study of i.v. granisetron in children undergoing highly emetogenic chemotherapy","volume":"12","author":"Leclerc JM","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90296-P"},{"key":"e_1_2_6_85_2","first-page":"259","article-title":"Oral granisetron solution as prophylaxis for chemotherapy\u2010induced emesis in children: Double\u2010blind study of 2 doses","volume":"87","author":"Mabro M","year":"2000","journal-title":"Bull Cancer"},{"key":"e_1_2_6_86_2","first-page":"673","article-title":"Effects of granisetron in children undergoing high\u2010dose chemotherapy: A multi\u2010institutional, cross\u2010over study","volume":"14","author":"Tsuchida Y","year":"1999","journal-title":"Int J Oncol"},{"key":"e_1_2_6_87_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950250607"},{"key":"e_1_2_6_88_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019509009478"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199408000-00010"},{"key":"e_1_2_6_90_2","first-page":"153","article-title":"Suppression of emetic cytostatic effect with tropisetron (Navoban) preventive application in paediatric patients","volume":"40","author":"Cepulic M","year":"1996","journal-title":"Paediatria Croatica"},{"key":"e_1_2_6_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/4.suppl_3.S35"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(05)80423-X"},{"issue":"5","key":"e_1_2_6_93_2","first-page":"17","article-title":"Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies","volume":"21","author":"Otten J","year":"1994","journal-title":"Semin Oncol"},{"key":"e_1_2_6_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/29.2.92"},{"key":"e_1_2_6_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089169408000610"},{"key":"e_1_2_6_96_2","first-page":"72","article-title":"Use of Navoban (tropisetron) in pediatric oncology","volume":"42","author":"Safonova SA","year":"1996","journal-title":"Voprosy Onkologii"},{"key":"e_1_2_6_97_2","first-page":"208","article-title":"Tropisetron in the prevention of chemotherapy\u2010induced vomiting in children with cancer","volume":"11","author":"Stary J","year":"1998","journal-title":"Klinicka Onkologie"},{"key":"e_1_2_6_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)00276-B"},{"key":"e_1_2_6_99_2","first-page":"207","article-title":"Tropisetron in the prevention of chemotherapy\u2010induced acute emesis in pediatric patients","volume":"41","author":"Uysal KM","year":"1999","journal-title":"Turk J Pediatr"},{"key":"e_1_2_6_100_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019609030852"},{"key":"e_1_2_6_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199908)33:2<99::AID-MPO7>3.0.CO;2-P"},{"key":"e_1_2_6_102_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199907000-00007"},{"key":"e_1_2_6_103_2","doi-asserted-by":"publisher","DOI":"10.1080\/088800101316922029"},{"key":"e_1_2_6_104_2","doi-asserted-by":"publisher","DOI":"10.1080\/088800199277425"},{"key":"e_1_2_6_105_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7139.1232"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20138","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T23:35:46Z","timestamp":1700177746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,16]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1002\/pbc.20138"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20138","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,16]]}}}